BEXIMCO PHARMACEUTICALS LTD.
News Release
23 March 2006
Beximco Pharmaceuticals Ltd introduces Osefluto
fight against the Bird Flu
Leading drug manufacturer in Bangladesh Beximco Pharmaceuticals Limited
introduced yesterday (March 22, 2006) Oseflu capsule for the prevention and
treatment of human cases of Avian influenza (H5N1) causing Bird flu.
The capsule contains Oseltamivir 75 mg that ensures outstanding efficacy
against pandemic strains of influenza including reducing the severity and
duration of symptoms and the complications arising from any influenza infection
and mortality.
Due to its safety and effectiveness against pandemic strains of influenza, the
World Health Organization has recommended it in the event of an influenza
pandemic, a senior official of Beximco Pharma said.
Regarding the launching of the drug he said, although no bird flu virus is still
detected in Bangladesh, the country is at the risk of spreading of this virus as it
has been detected in a large volume in India and Myanmar, the neighbouring
countries of Bangladesh.
Meanwhile, different UN agencies expressed concern that Bangladesh might
have devastating consequences of this deadly contiguous disease, he added.
According to the company source, people can easily avoid Bird Flu by following
some simple guidelines in their daily life like eating properly boiled (70 C)
chicken and eggs, washing eggs and chickens before refrigeration, washing
hands, utensils with soaps and warm water, keeping children away from poultry
etc. People should not panic if they suspect to have Bird flu and should talk to
doctors within 48 hours and take proper medicines.
Although Avian influenza or Bird-flu is a contagious disease of animals caused by
viruses that normally infect only birds, it causes death of human beings also
specially people who are engaged with the poultry activities.
The drug is also effective against both Influenza type A and B. So it can be used
for treatment and prophylaxis of both Influenza type A and B.
Beximco Pharma has opened a 24hrs Bird Flu Hotline for doctors to
provide any kind of information on Bird Flu.
Various public awareness campaigns would soon be undertaken by Beximco
Pharma to aware general people about the protection measures and general
health information relating to Bird Flu.
For more information, please contact:
Beximco Pharmaceuticals Limited
+880 2 8619 151
Nazmul Hassan
Libertas Capital
+44 (0)20 7569 9650
Aamir Quraishi / James Patterson
Financial Dynamics +44 (0)20 7831 3113
David Yates About Beximco Pharmaceuticals Limited [LSE: BXP; DSE: BEXPHARMA]
Founded in 1976 and based in Dhaka, Bangladesh, BPL manufactures and sells generic pharmaceutical formulation products, active pharmaceutical ingredients and intravenous fluids. The Company also undertakes contract manufacturing for GlaxoSmithKline and is about to commence manufacturing for Novartis. The Company operates from a 20 acre site in Dhaka and currently employs over 1800 staff.
The Company's products are sold to retail outlets, medical institutions and other
pharmaceutical manufacturers in Bangladesh, in regional markets such as Pakistan,
Nepal and Myanmar and in other markets overseas, principally in East Africa (including Kenya) and South East Asia (including Singapore).
In the year ended 31 December 2004, the business generated turnover of approximately Taka 2.77 billion or 23.5 million (2003: Taka 2.52 billion or 21.4 million) and profits
after tax of approximately Taka 329.4 million or 2.8 million (2003: Taka 237.8 million or 2.0 million). As at 31 December 2004, BPL's net assets were approximately Taka 5.17 billion or 43.9 million.

Uck me he finally got one right , you selling Mr tosser or you gonna go quiet again just as it stops rising ?

Have I seen this name before "Dil"

You are emulating the STAKER who dispatches perfumed rat.

Was shagging Sheep on WALES countryside TV

Some posters hate the shagger and its antics..................

ramperdil - 07 Dec 2005 22:03 - 13 of 1314
I would bring back hanging and start off with Dil.

ramperdil - 07 Dec 2005 22:41 - 16 of 1314
yes lets invade Wales and execute people like Dil.

BREAKOUT

42 / 44p +1.50p

is riding now as buyers are appearing, hardly any sells for some time, and large buys have been around from time to time

the same is happening on Bangladesh

10 days

3 month

Further movement UP and at the moment is 2p, so continuing with the BREAKOUT

Following yesterday's rise after retracement, spread 44 / 46p +0.75p

very strong also at Bangladesh, just short of the previous BREAKOUT 190.90 taka

Bangladesh price

at the exchange of 1.00 GBP = 106.828 BDT
That represents a 178p, close to 4 time cheaper over here

48 / 49p +1p

5 MMs have move up prices resulting on the move up
Since yesterday we are on a higher BREAKOUT

The management of BXP are due in London w/e 8th May.

The introduction of fungibility is a posibility at this stage. This could improve this share price on the short and long term pretty.

EK's tip of the year from Master Investor!

It's an event that was on Saturday.

www.masterinvestor.co.uk

Moving ahead now 50 / 51p +1.50p

with 3 MMs at bid price for 1 at offer

Looks like the MMs decided is time for retracement sice it reached 50p bid and would not take stock at that price though there was 3 MMS at bid, since any sell like yesterday of 3.5K and marked down on the bid 49p, today with 48p and now is 47p

On previous retracements about 50% of the risers were eroded and started a new movement UP.

In Bangladesh have also move lower from the almost TOP again a couple days ago.

It seems this weekend on Bangladesh the shares had a large drop to support to 166 taka and a bit of a bounce this morning

10 days

3 month

Are the shares ready to bounce now 35p?

some nibling over here as the Indicators are well at oversold.
Back in Bangladesh had already started to bounce back since last week

Not much is happening

HALF year results and they are good .............

Beximco Pharma pre-tax profits up 83%

Pre-tax profits at Dhaka-based Beximco Pharmaceuticals rose by 83% to BDT697.3m in the six months to the end of June.

Net sales increased by 28% to BDT2,968.7m with domestic sales up 28% to BDT2,825.9m and export sales rising 33.6% to BDT142.7m.

Managing director Nazmul Hassan said: "We strongly believe that we have significant scope to grow both in domestic and overseas markets, and our investments in expanding capacity and upgrading our facilities will provide the necessary impetus for long-term sustainable growth.

"Our new OSD facility will have increased capacity, with an additional three production lines commissioned, and the construction of our new MDI facility is nearing completion which will further expand capacity, enabling us to cater to growing demand."

33.50 / 34p +0.25p

Moving higher on the bid as buyers are piling in now. All buys today, as the volume is one of the highest for some time

Good size buying with only 1 MM at offer

Up on the offer after EVO ( Market Maker ) decided to let it go after the large amount of buys last Friday, though most of the trades were done by WINS at 33.8 / 33.9p

34 - 35p +0.75p

Maybe the fun have finally started, as another movement on the share price now on the bid side.

Trades are being shown on the ticker much often now.

Moving higher in Bangladesh to 151.80 +2.60

Evil discusses Avocet Mining, Europa Oil & Gas, Beximco Pharma and the outlook for metals prices. The (new) Idiot Diarist writes ........

I bought 250,000 Beximco Pharma (BXP) at 36p. This was partly because the stock was there (I thought I would get 50,000 at most) but also because there are now sufficient shareholders holding sufficient shares to spur the company and its advisers into action. The first target is Bank of New York Mellon (colloquially known as Boney M) which charges two cents a year per share for maintaining the London GDR register. This charge is palpably absurd. Given that the notice period required with which to dispense BNYM's services is 120 days, this should be put to bed forthwith. Failing which I suspect legal action follows. I trust Libertas, as Nomad, is ready to respond.